-$0.59 Earnings Per Share Expected for Strongbridge Biopharma plc (SBBP) This Quarter

Equities analysts predict that Strongbridge Biopharma plc (NASDAQ:SBBP) will post ($0.59) earnings per share for the current quarter, Zacks reports. Four analysts have made estimates for Strongbridge Biopharma’s earnings. The highest EPS estimate is ($0.46) and the lowest is ($0.71). Strongbridge Biopharma posted earnings of ($0.31) per share in the same quarter last year, which indicates a negative year over year growth rate of 90.3%. The business is scheduled to report its next quarterly earnings results on Monday, March 11th.

According to Zacks, analysts expect that Strongbridge Biopharma will report full-year earnings of ($1.74) per share for the current fiscal year, with EPS estimates ranging from ($1.89) to ($1.59). For the next year, analysts forecast that the firm will report earnings of ($0.99) per share, with EPS estimates ranging from ($1.15) to ($0.82). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that follow Strongbridge Biopharma.

Strongbridge Biopharma (NASDAQ:SBBP) last announced its earnings results on Wednesday, October 31st. The biotechnology company reported ($0.44) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.38) by ($0.06). The firm had revenue of $5.35 million for the quarter, compared to the consensus estimate of $5.48 million.

Several brokerages have recently commented on SBBP. Zacks Investment Research downgraded shares of Strongbridge Biopharma from a “hold” rating to a “sell” rating in a report on Wednesday, November 7th. ValuEngine downgraded shares of Strongbridge Biopharma from a “buy” rating to a “hold” rating in a report on Monday, November 12th. Cantor Fitzgerald set a $17.00 price objective on shares of Strongbridge Biopharma and gave the stock a “buy” rating in a report on Wednesday, October 31st. Finally, BidaskClub downgraded shares of Strongbridge Biopharma from a “sell” rating to a “strong sell” rating in a report on Wednesday, September 5th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company’s stock. Strongbridge Biopharma presently has a consensus rating of “Hold” and a consensus target price of $14.75.

A number of hedge funds and other institutional investors have recently bought and sold shares of SBBP. Laurion Capital Management LP purchased a new stake in Strongbridge Biopharma during the second quarter worth about $101,000. Dynamic Technology Lab Private Ltd purchased a new stake in Strongbridge Biopharma during the second quarter worth about $110,000. Cubist Systematic Strategies LLC purchased a new stake in Strongbridge Biopharma during the second quarter worth about $130,000. Jane Street Group LLC purchased a new stake in Strongbridge Biopharma during the second quarter worth about $154,000. Finally, Citadel Advisors LLC purchased a new stake in Strongbridge Biopharma during the third quarter worth about $157,000. Institutional investors and hedge funds own 65.68% of the company’s stock.

Shares of SBBP stock opened at $4.37 on Friday. The company has a current ratio of 3.38, a quick ratio of 3.11 and a debt-to-equity ratio of 8.76. Strongbridge Biopharma has a one year low of $3.85 and a one year high of $9.25.

About Strongbridge Biopharma

Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company's commercial products include Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States; and Macrilen, an oral growth hormone secretagogue receptor agonist for use in the diagnosis of patients with adult growth hormone deficiency in the United States and Canada.

Read More: Compound Annual Growth Rate (CAGR)

Get a free copy of the Zacks research report on Strongbridge Biopharma (SBBP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Strongbridge Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply